Table 1 Virologic, epidemiologic, histologic, laboratory, and clinical characteristics of 102 patients with HCV-related cryoglobulinemic vasculitis
From: Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia
Virology | |
|---|---|
Serum HCV RNA, n (%) | 102 (100) |
• Titer, log IU/ml, median (range) | 5.64 (4.0-7.0) |
Serum HCV core protein, n (%) | 102 (100) |
• Titer, pg/ml, median (range) | 18.3 (1.3-175.6) |
Cryoprecipitate core protein, n (%) | 102 (100) |
• Titer, pg/ml, median (range) | 18.5 (0.1-105) |
Supernatant core protein, n (%) | 102 (100) |
• Titer , pg/ml, median (range) | 3.1 (0.2-91.3) |
HCV Genotype, n (%) | |
• gt-1 | 51 (50) |
• gt-2 | 49 (48.1) |
• gt-3 | 2 (1.9) |
Anti-HCV antibodies, n (%) | 102 (100) |
HBsAg, n (%) | 0 |
Anti-HIV antibodies, n (%) | 0 |
Epidemiology | |
Sex: M/F (ratio) | 22/80 (0.27) |
Age, years, median (range) | 68 (44–80) |
Presumed duration of cryoglobulinemic vasculitis, years, median (range) | 7.5 (1–26) |
Blood/blood product transfusion, n (%) | 24 (23.5) |
Liver histology | |
Chronic active hepatitis, n (%) | 92 (90.2) |
Inflammation index, median (range) | 3.1 (2.8-4.4) |
Fibrosis index, median (range) | 2.2 (1.6-3.8) |
Cirrhosis, n (%) | 10 (9.8) |
Laboratory | |
Cryocrit, %, median (range) | 5 (1–16) |
Immunochemical type | |
• II, n (%) | 96 (94.1) |
• III, n (%) | 6 (5.9) |
Rheumatoid factor, (IU/ml, ≤20), median (range) | 174 (20–4,470) |
Immunoglobulins | |
• IgM (mg/dl, 40–230), median (range) | 255 (17–1,273) |
• IgG (mg/dl, 700–1,600), median (range) | 1,180 (151–2,220) |
Complement fraction | |
• C1q (mg/dl, 21–39), median (range) | 36.5 (25–141) |
• C3 (mg/dl, 90–180), median (range) | 97.8 (4.1-228) |
• C4 (mg/dl, 10–40), median (range) | 3.15 (1–22) |
ALT (IU/L, 30–65), median (range) | 49 (19–265) |
GGT (IU/L, 5–55), median (range) | 57.5 (31–145) |
Peripheral lymphocytogram | |
CD3 (%, 72 ± 10.2), median (range) | 74 (36–89) |
CD20 (%, 10.2 ± 5.4), median (range) | 16 (5–73) |
Symptoms | |
Palpable purpura, n (%) | 85 (83.3) |
Weakness, n (%) | 61 (59.8) |
Arthralgias/nonerosive arthritis, n (%) | 66 (64.7) |
Cutaneous ulcers, n (%) | 40 (39.2) |
Peripheral neuropathies, n (%) | 36 (35.3) |
Renal disease, n (%) | 24 (23.5) |
Membranoproliferative glomerulonephritis, n (%) | 19 (79.2) |
Nephrotic syndrome, n (%) | 5 (20.8) |